Pharmanutra S.p.A., headquartered in Italy, is a leading player in the nutraceutical and pharmaceutical industry, specialising in the development of innovative dietary supplements and medical devices. Founded in 2003, the company has achieved significant milestones, including the introduction of its flagship product, SiderAL, which is renowned for its unique formulation of iron and its high bioavailability. With a strong presence in Europe and expanding operations in international markets, Pharmanutra is committed to enhancing health and well-being through scientifically-backed solutions. The company’s core offerings, including SiderAL and other mineral-based supplements, are distinguished by their patented technologies and rigorous clinical research. Recognised for its excellence, Pharmanutra continues to solidify its market position as a trusted provider of high-quality health products, contributing to advancements in nutritional science.
How does Pharmanutra's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Pharmanutra's score of 33 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Pharmanutra reported total carbon emissions of approximately 1,182,014 kg CO2e. This figure includes 229,189 kg CO2e from Scope 1 emissions, 270,515 kg CO2e from Scope 2 emissions (market-based), and significant Scope 3 emissions of 751,110 kg CO2e, which comprise 684,328 kg CO2e from business travel and 86,782 kg CO2e from employee commuting. Pharmanutra's emissions have shown fluctuations over the years. In 2022, the company recorded total emissions of about 199,150 kg CO2e for Scope 1 and 57,666 kg CO2e for Scope 2 (market-based). The previous year, 2021, saw Scope 1 emissions at 137,965 kg CO2e and Scope 2 emissions at 42,922 kg CO2e (market-based). In 2020, the company reported 92,590 kg CO2e for Scope 1 and 61,095 kg CO2e for Scope 2. Despite these figures, Pharmanutra has not disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of defined climate pledges or science-based targets indicates a potential area for improvement in their sustainability strategy. As the company continues to operate within the pharmaceutical industry, addressing carbon emissions will be crucial for aligning with global climate commitments and enhancing their environmental responsibility.
Access structured emissions data, company-specific emission factors, and source documents
2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|
Scope 1 | 92,590 | 000,000 | 000,000 | 000,000 |
Scope 2 | 61,095 | 00,000 | 00,000 | 000,000 |
Scope 3 | - | - | - | 000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Pharmanutra is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.